Login to Your Account

Inotrem lands $25M to fund sepsis R&D, focuses on the TREM-1 path

By Nuala Moran
Staff Writer

Monday, March 17, 2014
A new company has been founded with €18million (US$25 million) in series A funding to have another go at scaling the sheer cliffs of sepsis. Inotrem SA will focus on the TREM-1 (triggering receptor expressed on myeloid cells) pathway, which functions as an amplifier of the immune response and is markedly up-regulated in patients suffering from sepsis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription